Prophylaxis News and Research

RSS

Study: Using best-practice approach could lead to big cost reductions in hospitals nationwide

A major challenge facing today's health care community is to find ways to lower costs without compromising clinical quality. Taking that challenge to task, researchers at Medstar Health and Georgetown University School of Medicine, Washington DC, report success in using a concept called "value-based analysis," which simultaneously measures quality and cost and addresses inefficiencies in care.

11 Apr 2013

FDA accepts Merck's NDA for NOXAFIL tablets

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration.

11 Apr 2013

New study suggests that Ranibizumab can be potential prophylaxis for PVR

Proliferative vitreoretinopathy, or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, lacks effective treatment options, and substantially reduces an individual's quality of life.

10 Apr 2013

Research shows immune system can destroy HIV through deactivation of vif gene

Human cells have an intrinsic capacity to destroy HIV. However, the virus has evolved to contain a gene that blocks this ability. When this gene is removed from the virus, the innate human immune system destroys HIV by mutating it to the point where it can no longer survive.

29 Mar 2013

POZEN announces submission of NDA for marketing approval of PA32540/PA8140

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the marketing approval of PA32540/PA8140.

27 Mar 2013

Dialysis patients face increased risk of antibiotic-resistant infections

Patients who receive hemodialysis are at a significant risk of developing infections, a leading cause of hospitalization and death in this patient population.

13 Mar 2013

Listen to women's needs when designing HIV prevention strategies

According to "results from a large HIV prevention trial among African women" known as VOICE and released last week, "none of the prevention methods tested in the study made a difference in HIV infection rates, because few women actually used them as directed," AVAC Executive Director Mitchell Warren writes in an opinion piece published in the Huffington Post's "Global Motherhood" blog.

12 Mar 2013

Weight loss may help prevent and alleviate symptoms of osteoarthritis

Weight loss may prevent and significantly alleviate the symptoms of osteoarthritis, a progressive disease of the joints known as "wear and tear" arthritis, according to a literature review appearing in the March 2013 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS).

11 Mar 2013

Antibiotic prophylaxis after IVT may be harmful

Researchers are warning against routine antibiotic prophylaxis with intravitreal injection after finding that the practice can increase the antibiotic resistance of ocular surface flora.

6 Mar 2013

AHRQ releases Making Health Care Safer II report

The Agency for Healthcare Research and Quality (AHRQ) has released a new report, Making Health Care Safer II, which identifies the top 10, evidence-based patient safety strategies available to clinicians.

6 Mar 2013

Study shows community-based HIV-prevention efforts increase testing rates, reduce HIV incidence

In Africa and Thailand, communities that worked together on HIV-prevention efforts saw not only a rise in HIV screening but a drop in new infections, according to a new study presented this week at the Conference on Retroviruses and Opportunistic Infections in Atlanta.

6 Mar 2013

Good dental health ‘cuts stroke risk’

Good dental health, including prophylaxis of periodontal disease, is associated with a reduced risk for ischemic stroke, results of a large retrospective cohort study indicate.

5 Mar 2013

Biogen announces FDA acceptance of rFIXFc BLA for treatment of hemophilia B

Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B and granted the company a standard review timeline.

5 Mar 2013

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.

From Baxter International Inc. 26 Feb 2013

Dabigatran decreases risk of recurrent venous thromboembolism

New findings from two double-blind, randomized trials, RE-MEDY and RE-SONATE, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE).

21 Feb 2013

CCR1 and CCR5 receptors play a crucial role in atherosclerosis

Atherosclerosis is one of the commonest causes of death in modern societies. The condition is characterized by the build-up of fatty deposits called atherosclerotic plaques on the inner surfaces of arteries, which restrict, and may eventually cut off, blood flow. The deposits can also be dislodged from their site of origin and may then block major vessels in the heart or the brain, leading to life-threatening myocardial infarction or stroke.

20 Feb 2013